ID   PAX-C002
AC   CVCL_D7E6
SY   PAXC002
DR   CCRID; 4201PAT-CCTCC00330
DR   EFO; EFO_0022552
RX   Patent=CN102329775B;
RX   PubMed=22076649;
RX   PubMed=22325559;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201010.
CC   Population: Chinese.
CC   Characteristics: Established from a xenograft produced by subcutaneous injection of tumor cells into SCID mice (PubMed=22076649).
CC   Characteristics: Gemcitabine resistant (Patent=CN102329775B; PubMed=22076649).
CC   Doubling time: 47.65 hours (Patent=CN102329775B); ~48 hours (PubMed=22076649).
CC   Derived from site: In situ; Pancreas; UBERON=UBERON_0001264.
ST   Source(s): PubMed=22325559
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 11,12
ST   D16S539: 9
ST   D5S818: 12
ST   D7S820: 8,9
ST   TH01: 7,9
ST   TPOX: 8,11
ST   vWA: 16,18
DI   NCIt; C9120; Pancreatic ductal adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   56Y
CA   Cancer cell line
DT   Created: 10-09-24; Last updated: 10-09-24; Version: 1
//
RX   Patent=CN102329775B;
RA   Qin X.-R., Zhu M.-H., Hu G., Xie F.-B., Tang X.-Z., Wen D.-Y.;
RT   "Gemcitabine-tolerant human pancreatic cancer cell line and
RT   application thereof.";
RL   Patent number CN102329775B, 19-Aug-2015.
//
RX   PubMed=22076649; DOI=10.3892/ijo.2011.1254;
RA   Hu G., Li F., Ouyang K.-D., Xie F.-B., Tang X.-Z., Wang K., Han S.-F.,
RA   Jiang Z.-Z., Zhu M.-H., Wen D.-Y., Qin X.-R., Zhang L.-Y.;
RT   "Intrinsic gemcitabine resistance in a novel pancreatic cancer cell
RT   line is associated with cancer stem cell-like phenotype.";
RL   Int. J. Oncol. 40:798-806(2012).
//
RX   PubMed=22325559; DOI=10.1111/j.1742-4658.2012.08521.x;
RA   Li F., Hu G., Jiang Z.-Z., Guo J., Wang K., Ouyang K.-D., Wen D.-Y.,
RA   Zhu M.-H., Liang J.-X., Qin X.-R., Zhang L.-Y.;
RT   "Identification of NME5 as a contributor to innate resistance to
RT   gemcitabine in pancreatic cancer cells.";
RL   FEBS J. 279:1261-1273(2012).
//